Genetic Risk Factor for Heat Stroke
NCT06847256 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2026-04-27
Summary
The goal of this observational study is to examine the effect of the Cystic Fibrosis (CF) Carrier state on the risk for dehydration and other CF-specific fluid-and-electrolyte disorders in male and female adults.
The primary aim of the study is to estimate the risk of electrolyte disorders attributable to the CF carrier state in a genotyped cohort.
This will be accomplished with two smaller projects- Aim 1 and Aim 2.
Aim 1 will consist of 100 CF Carriers and 100 age- and sex-matched controls. Participants in this aim will be asked to complete a Participant Info and Temperature Survey consisting of questions about race, ethnicity, medical history, and how they experience heat.
Aim 2 will consist of a subset of 25 CF Carriers and 25 age- and sex-matched controls from Aim 1. Participants in this aim will be scheduled for a visit to complete a heat challenge. At this visit, they will also complete the Participant Info and Temperature Survey. They will also sit in a sauna at 62 - 63 degrees Celsius for 45 minutes.
Conditions
- Carrier State
- Heat Stroke
- Dehydration
Interventions
- PROCEDURE
-
Heat Challenge
Participants will be asked to arrive well-hydrated and to refrain from exercise, alcohol, caffeine, and smoking for 24 hours prior to the visit. Height, weight, blood pressure, and body fat percentage will be measured. Blood (15.5 ml) and urine will be collected. Participants will wear a heart rate monitor and sit in a heat chamber at 62-63 degrees Celsius for 45 minutes. Heart rate will be measured continuously. Body temperature and a self-report of their comfort (1-4 scale) and thermosensation (1-7 scale) will be measured before the challenge, every 15 minutes during the challenge, and after the challenge. During the challenge, a sample of sweat will be collected to measure electrolyte loss. Participants will consume 16 ounces of water at their own pace during the 45 minutes. If they become too uncomfortable to continue or their body temperature rises above 39 degrees Celsius, the challenge will be stopped. All baseline measures except body fat percentage will be measured again.
Sponsors & Collaborators
-
University of Iowa
lead OTHER
Principal Investigators
-
Aaron Miller, PhD · University of Iowa
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-19
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- United States
Study Locations
More Related Trials
-
Genetics of Insulin and Incretins in Cystic Fibrosis
NCT01852448 ·Status: RECRUITING
-
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
NCT05998629 ·Status: RECRUITING ·Phase: NA
-
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
NCT05639556 ·Status: ACTIVE_NOT_RECRUITING
-
Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)
NCT02690519 ·Status: COMPLETED ·Phase: PHASE2
-
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
NCT03350828 ·Status: ACTIVE_NOT_RECRUITING
-
Diagnosis and Treatment of Patients With Cystic Fibrosis
NCT00001223 ·Status: TERMINATED
-
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
NCT01805713 ·Status: COMPLETED
-
Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis
NCT05239611 ·Status: COMPLETED ·Phase: PHASE2
-
Redox Imbalance and the Development of Cystic Fibrosis Diabetes
NCT02202876 ·Status: COMPLETED ·Phase: NA
-
The Relationship Between CFTR Gene Mutations and Exercise Capacity
NCT05157646 ·Status: WITHDRAWN ·Phase: NA
-
Development of Diabetes in Adults With Cystic Fibrosis (CF)
NCT03644199 ·Status: WITHDRAWN ·Phase: NA
-
Genetic Modifiers of Cystic Fibrosis Related Diabetes
NCT01113216 ·Status: ENROLLING_BY_INVITATION
-
BioEnergetics and Metabolomics in Cystic Fibrosis
NCT02225899 ·Status: COMPLETED
-
Thoracic Mobility in Cystic Fibrosis Care
NCT04696198 ·Status: COMPLETED ·Phase: NA
-
Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients
NCT00376428 ·Status: TERMINATED ·Phase: PHASE2
-
Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.
NCT03589313 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
NCT02392234 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Fat Free Mass Index and Its Impact on Health in Children With Cystic Fibrosis
NCT01401439 ·Status: COMPLETED
-
Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
NCT05474430 ·Status: RECRUITING
-
Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients
NCT00506688 ·Status: COMPLETED ·Phase: PHASE2
-
Measurement of Beta Cell Death in Individuals With Cystic Fibrosis
NCT03713437 ·Status: COMPLETED
-
Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance
NCT02776098 ·Status: COMPLETED
-
Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)
NCT00082238 ·Status: COMPLETED ·Phase: NA
-
Muscle Function and Physical Activity in the Modern Era of Cystic Fibrosis
NCT06251622 ·Status: RECRUITING
-
Evaluation of Salt Status in Patients With Cystic Fibrosis
NCT04556162 ·Status: COMPLETED